Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Long Term Results ◽

Breast Cancer Patients ◽

Single Institution ◽

Heavily Pretreated

Long-Term Results of Post Mastectomy Conformal Electron Therapy Technique (PMERT) with Bolus in Comparison with Post Mastectomy Conformal Photon Therapy (PMPhRT) without Bolus in Non-Metastatic Breast Cancer Patients

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2018.07.1573 ◽

2018 ◽

Vol 102 (3) ◽

pp. e567

Author(s):

G. Boulle ◽

C. Saint Martin ◽

N. Fournier Bidoz ◽

F. Berger ◽

A. Veret ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Long Term Results ◽

Breast Cancer Patients ◽

Electron Therapy ◽

Therapy Technique

Safety and efficacy of non-pegylated liposomal doxorubicin (NPLD) in HER2 negative metastatic breast cancer (mBC) patients (PTS) as second-line (2L) and beyond: a restrospective single institution analysis

Annals of Oncology ◽

10.1093/annonc/mdx424.061 ◽

2017 ◽

Vol 28 ◽

pp. vi42

Author(s):

C. De Angelis ◽

L. Diodati ◽

I. Bertolini ◽

I. Montagnani ◽

A. Fontana ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Second Line ◽

Single Institution ◽

Safety And Efficacy

Non Pegylated Liposomal Doxorubicin Beyond the First Line Treatment of Metastatic Breast Cancer Patients: A Retrospective Analysis

Annals of Oncology ◽

10.1016/s0923-7534(20)32919-7 ◽

2012 ◽

Vol 23 ◽

pp. ix128-ix129

Author(s):

S. Bernhard ◽

L. Mansi ◽

V. Nerich ◽

C.B. Villanueva ◽

E. Dobi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Line Treatment ◽

Breast Cancer Patients ◽

First Line ◽

First Line Treatment

Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study

Annals of Oncology ◽

10.1093/annonc/mdr024 ◽

2011 ◽

Vol 22 (12) ◽

pp. 2591-2596 ◽

Cited By ~ 20

Author(s):

M. Martín ◽

P. Sánchez-Rovira ◽

M. Muñoz ◽

J.M. Baena-Cañada ◽

J.R. Mel ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Cardiac Safety ◽

Her2 Positive

Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients

American Journal of Clinical Oncology ◽

10.1097/coc.0b013e3182005783 ◽

2012 ◽

Vol 35 (1) ◽

pp. 18-21 ◽

Cited By ~ 11

Author(s):

Jean-Philippe Jacquin ◽

Cyrus Chargari ◽

Julie Thorin ◽

Dominique Mille ◽

Adrien Mélis ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients

Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial

European Journal of Cancer ◽

10.1016/j.ejca.2013.04.027 ◽

2013 ◽

Vol 49 (13) ◽

pp. 2806-2814 ◽

Cited By ~ 19

Author(s):

C. Falandry ◽

E. Brain ◽

M. Bonnefoy ◽

F. Mefti ◽

N. Jovenin ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Breast Cancer Patients

Feasibility and Cardiac Safety of Pegylated Liposomal Doxorubicin plus Trastuzumab in Heavily Pretreated Patients with Recurrent HER2-Overexpressing Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2007.n.028 ◽

2007 ◽

Vol 7 (9) ◽

pp. 690-696 ◽

Cited By ~ 21

Author(s):

Eleni Andreopoulou ◽

Darci Gaiotti ◽

Eugene Kim ◽

Matthew Volm ◽

Ruth Oratz ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Cardiac Safety ◽

Heavily Pretreated ◽

Pretreated Patients

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-005-0116-2 ◽

2005 ◽

Vol 57 (5) ◽

pp. 615-623 ◽

Cited By ~ 17

Author(s):

Alessandra Fabi ◽

Gianluigi Ferretti ◽

Paola Papaldo ◽

Nello Salesi ◽

Mariangela Ciccarese ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients

Pegylated liposomal doxorubicin (PLD) and gemcitabine in the treatment of metastatic breast cancer: A single-institution experience.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.e11510 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e11510-e11510

Author(s):

J. Espinós ◽

A. Hernández ◽

A. Castillo ◽

M. Zudaire ◽

O. Fernández-Hidalgo ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Single Institution

Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report

The Breast ◽

10.1016/j.breast.2009.10.003 ◽

2010 ◽

Vol 19 (1) ◽

pp. 33-37 ◽

Cited By ~ 21

Author(s):

E. Munzone ◽

A. Di Pietro ◽

A. Goldhirsch ◽

I. Minchella ◽

E. Verri ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Case Series ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Case Series Report ◽

Metronomic Administration ◽

Series Report